Vanda Pharmaceuticals Reports Second Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 3c
July 28, 2021 4:09 PM EDTVanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.17, $0.03 better than the analyst estimate of $0.14. Revenue for the quarter came in at $67.9 million versus the consensus estimate of $69.75 million.
GUIDANCE:
Vanda expects to achieve the following financial objectives in 2021:
... More